Denali Therapeutics Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026The company received a large cash payment by selling a valuable FDA voucher it earned from approving a Hunter syndrome drug.
Selling valuable FDA vouchers generates immediate cash that funds drug development without diluting shareholders.
Annual meetings show how shareholders vote on company leadership and manager compensation, which affects company direction.
Drug trial results move companies closer to selling medicines and help investors understand if treatments work.
Quarterly reports show whether the company is spending money wisely and how long cash will last.
Earnings announcements reveal company revenue, losses, and cash position that affect stock price.
Lost partnerships can hurt a company's drug pipeline, but regaining rights lets Denali find new partners.
Stocky reads Denali Therapeutics Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Denali Therapeutics Inc.'s most recent tracked filing was a 8-K on 28 Jul 2026: Sold rare disease voucher for $195 million to pharma company.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.